Maynard Um
-
-
-
-
-
-
-
Arvinas shares gain as FDA approves breast cancer drug Veppanu
-
-
-
-
-
-
-
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
-
-
-
-
-
-
-
Arvinas presents preclinical data for cancer drug ARV-806
-
-
-
-
-
-
-
Arvinas Inc. (ARVN) PT Lowered to $15 at Barclays
-
-
-
-
-
-
-
Arvinas Inc. (ARVN) PT Lowered to $15 at Guggenheim
-
-
-
-
-
-
-
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
-
-
-
-
-
-
-
Jefferies Downgrades Arvinas Inc. (ARVN) to Hold
-
404,876 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

